GEN-MKT-18-7897-A
Jun 5, 2017 | Blogs, Pharma | 0 comments
If you work in the breakneck world of therapeutic development, then you probably don’t even have time to read this blog (but we thought we would write it anyways, just in case). Drug metabolism samples are coming into your lab fast and furious. You need to turn them around in hours so that chemists and biologists can optimize the effectiveness of the therapeutic candidate. Time for lunch? We don’t think so!
The chances are that you know about high-throughput LC-MS techniques, you probably even know that you need to adopt them, but where do you start? We know how demanding routine biotransformation studies can be, so we have done our best to make this as easy for you as possible with a solution that came from very clear objectives.
We wanted to help you maximize compound analysis while reducing method development time. We wanted to impress you with fast, automated data processing to identify the top metabolites and soft spots. We wanted to give you absolute confidence in the data report, and in a format that a medicinal chemist would like to see. We wanted to give you assurances in instrument uptime so you can just focus on getting the answers you need. We wanted you to have time for lunch!
We bring you the Routine Biotransform Solution, a simple and streamlined platform for high-throughput MetID analyses for both small and large molecule therapeutics. The compact, easy-to-use instrumentation and powerful automated data processing software helps you achieve new levels of productivity and throughput to boost performance and keep your projects moving.
We have crammed in as much of our best-in-class LC-MS technology as we possibly can, making routine ID of the top metabolites and biotherapeutic catabolites as simple and fast as possible. Fully integrated into one complete solution, you benefit from:
We know it is a lot to take in, but if you need high-throughput, then you need a solution as powerful as the Routine Biotransform Solution from SCIEX. For further information on how you can transform your biotransformation studies download the information pack today.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network